Health Utilities Associated with Hemoglobin Levels and Blood Loss in Postmenopausal Women: The Women's Health Initiative

Harrow, Brooke; Eaton, Charles B.; Roberts, Mary B.; Assaf, Annlouise R.; Luo, Xuemei; Zhao, Chen

doi:10.1016/j.jval.2010.11.008

Cited by 7 publications

(13 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the selected 21 articles (Table 2 ), 20 (95.2%) regarded observational studies [ 8 , 14 – 18 , 26 , 27 , 29 – 40 ]. Of these, 10 (50.0%) were cross-sectional studies [ 16 – 18 , 30 – 34 , 37 , 38 ] and 10 (50.0%), cohort studies (9 prospective [ 8 , 14 , 15 , 27 , 29 , 35 , 36 , 39 , 40 ] and 1 retrospective [ 26 ]). In addition, an experimental study of which only baseline data was used for analysis was included [ 28 ].…”

Section: Resultsmentioning

confidence: 99%

“…4). Although less studied, statistically significant associations were also observed between the presence of renal failure [8,14,16,30], thyroid gland dysfunction [8], neoplasms [16,26,35,36] or obesity [8,30], and a worse HRQoL in patients with HF ( Fig. 4).…”

Section: Comorbidity and Health-related Quality Of Lifementioning

confidence: 99%

“…Finally, from the 3 systematic reviews, 6 articles were selected that met the inclusion criteria. Finally, 21 articles were selected [8,[14][15][16][17][18][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40]. Additional file 4 provides a list of included and excluded studies along with reasons for exclusion.…”

Section: Data Synthesis and Presentationmentioning

confidence: 99%

“…In general, the selected studies were of acceptable quality, although many did not provide sufficient information about threats to internal validity. However, 33.3% (7 of 21) of the studies were considered to be of good quality [15,26,27,29,35,39,40]. These studies stood out for their transparency and control of threats to internal validity.…”

Section: Quality Of the Selected Studiesmentioning

confidence: 99%

See 3 more Smart Citations

Impact of non-cardiovascular comorbidities on the quality of life of patients with chronic heart failure: a scoping review

Comín‐Colet

Lorenzo

González-Domínguez

et al. 2020

Health Qual Life Outcomes

View full text Add to dashboard Cite

Purpose To determine the impact of non-cardiovascular comorbidities on the health-related quality of life (HRQoL) of patients with chronic heart failure (CHF). Methods A scoping review of the scientific literature published between 2009 and 2019 was carried out. Observational studies which assessed the HRQoL of patients with CHF using validated questionnaires and its association with non-cardiovascular comorbidities were included. Results The search identified 1904 studies, of which 21 fulfilled the inclusion criteria to be included for analysis. HRQoL was measured through specific, generic, or both types of questionnaires in 72.2%, 16.7%, and 11.1% of the studies, respectively. The most common comorbidities studied were diabetes mellitus (12 studies), mental and behavioral disorders (8 studies), anemia and/or iron deficiency (7 studies), and respiratory diseases (6 studies). Across studies, 93 possible associations between non-cardiovascular comorbidities and HRQoL were tested, of which 21.5% regarded anemia or iron deficiency, 20.4% mental and behavioral disorders, 20.4% diabetes mellitus, and 14.0% respiratory diseases. Despite the large heterogeneity across studies, all 21 showed that the presence of a non-cardiovascular comorbidity had a negative impact on the HRQoL of patients with CHF. A statistically significant impact on worse HRQoL was found in 84.2% of associations between mental and behavioral disorders and HRQoL (patients with depression had up to 200% worse HRQoL than patients without depression); 73.7% of associations between diabetes mellitus and HRQoL (patients with diabetes mellitus had up to 21.8% worse HRQoL than patients without diabetes mellitus); 75% of associations between anemia and/or iron deficiency and HRQoL (patients with anemia and/or iron deficiency had up to 25.6% worse HRQoL than between patients without anemia and/or iron deficiency); and 61.5% of associations between respiratory diseases and HRQoL (patients with a respiratory disease had up to 21.3% worse HRQoL than patients without a respiratory disease). Conclusion The comprehensive management of patients with CHF should include the management of comorbidities which have been associated with a worse HRQoL, with special emphasis on anemia and iron deficiency, mental and behavioral disorders, diabetes mellitus, and respiratory diseases. An adequate control of these comorbidities may have a positive impact on the HRQoL of patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Comorbidity and Health-related Quality Of Lifementioning

confidence: 99%

Section: Data Synthesis and Presentationmentioning

confidence: 99%

Section: Quality Of the Selected Studiesmentioning

confidence: 99%

See 2 more Smart Citations

Impact of non-cardiovascular comorbidities on the quality of life of patients with chronic heart failure: a scoping review

Comín‐Colet

Lorenzo

González-Domínguez

et al. 2020

Health Qual Life Outcomes

View full text Add to dashboard Cite

show abstract

“…We used a recent NICE technology assessment of cancer treatment-induced anaemia (TA323) 182 to estimate the utility difference for anaemia. This assessment used estimates from Harrow et al, 181 scaled from the SF-6D to the EQ-5D, and was based on a cancer population.…”

Section: Disutilities For Adverse Eventsmentioning

confidence: 99%

The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation

Huxley

Crathorne

Varley-Campbell

et al. 2017

Health Technol Assess

View full text Add to dashboard Cite

BackgroundColorectal cancer is the fourth most commonly diagnosed cancer in the UK after breast, lung and prostate cancer. People with metastatic disease who are sufficiently fit are usually treated with active chemotherapy as first- or second-line therapy. Targeted agents are available, including the antiepidermal growth factor receptor (EGFR) agents cetuximab (Erbitux®, Merck Serono UK Ltd, Feltham, UK) and panitumumab (Vecitibix®, Amgen UK Ltd, Cambridge, UK).ObjectiveTo investigate the clinical effectiveness and cost-effectiveness of panitumumab in combination with chemotherapy and cetuximab in combination with chemotherapy for rat sarcoma (RAS) wild-type (WT) patients for the first-line treatment of metastatic colorectal cancer.Data sourcesThe assessment included a systematic review of clinical effectiveness and cost-effectiveness studies, a review and critique of manufacturer submissions, and a de novo cohort-based economic analysis. For the assessment of effectiveness, a literature search was conducted up to 27 April 2015 in a range of electronic databases, including MEDLINE, EMBASE and The Cochrane Library.Review methodsStudies were included if they were randomised controlled trials (RCTs) or systematic reviews of RCTs of cetuximab or panitumumab in participants with previously untreated metastatic colorectal cancer withRASWT status. All steps in the review were performed by one reviewer and checked independently by a second. Narrative synthesis and network meta-analyses (NMAs) were conducted for outcomes of interest. An economic model was developed focusing on first-line treatment and using a 30-year time horizon to capture costs and benefits. Costs and benefits were discounted at 3.5% per annum. Scenario analyses and probabilistic and univariate deterministic sensitivity analyses were performed.ResultsThe searches identified 2811 titles and abstracts, of which five clinical trials were included. Additional data from these trials were provided by the manufacturers. No data were available for panitumumab plus irinotecan-based chemotherapy (folinic acid + 5-fluorouracil + irinotecan) (FOLFIRI) in previously untreated patients. Studies reported results forRASWT subgroups. First-line treatment with anti-EGFR therapies in combination with chemotherapy appeared to have statistically significant benefits for patients who areRASWT. For the independent economic evaluation, the base-case incremental cost-effectiveness ratio (ICER) forRASWT patients for cetuximab plus oxaliplatin-based chemotherapy (folinic acid + 5-fluorouracil + oxaliplatin) (FOLFOX) compared with FOLFOX was £104,205 per quality-adjusted life-year (QALY) gained; for panitumumab plus FOLFOX compared with FOLFOX was £204,103 per QALY gained; and for cetuximab plus FOLFIRI compared with FOLFIRI was £122,554 per QALY gained. The ICERs were sensitive to treatment duration, progression-free survival, overall survival (resected patients only) and resection rates.LimitationsThe trials includedRASWT populations only as subgroups. No evidence was available for panitumumab plus FOLFIRI. Two networks were used for the NMA and model, based on the different chemotherapies (FOLFOX and FOLFIRI), as insufficient evidence was available to the assessment group to connect these networks.ConclusionsAlthough cetuximab and panitumumab in combination with chemotherapy appear to be clinically beneficial forRASWT patients compared with chemotherapy alone, they are likely to represent poor value for money when judged by cost-effectiveness criteria currently used in the UK. It would be useful to conduct a RCT in patients withRASWT.Study registrationThis study is registered as PROSPERO CRD42015016111.FundingThe National Institute for Health Research Health Technology Assessment programme.

show abstract

Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer from the perspective of the Chinese health-care system

Zhu,

Han,

2023

BMC Health Serv Res

View full text Add to dashboard Cite

Background Pembrolizumab is superior to chemotherapy as a first-line treatment for patients with mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer (CRC), with a significant long-term survival benefit according to the KEYNOTE-177 trial. The current study aimed to determine whether pembrolizumab is a cost-effective treatment for patients with dMMR/MSI-H advanced or metastatic CRC in China. Methods A partitioned survival model (PSM) was developed to simulate patients with dMMR/MSI-H advanced or metastatic CRC based on progression-free survival (PFS), progressive disease (PD) and death. The model was designed using a lifetime horizon, a 6-week cycle, and a 5% discount rate. The patients in the model had metastatic dMMR/MSI-H CRC and had not previously received treatment; these characteristics were similar to those of patients in KEYNOTE-177, a phase 3, open-label randomized clinical trial. The health outcomes and utilities were based on the KEYNOTE-177 trial and published data, respectively. Costs were calculated based on local charges (2022) and published literature. A treatment was deemed cost-effective in China if the incremental cost-effectiveness ratio (ICER) value was less than U.S.$38,142.56 per quality-adjusted life-year (QALY). The robustness of the results was assessed via one-way deterministic and probabilistic sensitivity analyses. Results Baseline analysis revealed that pembrolizumab provided an additional 2.58 QALYs (3.00 life-year) at an incremental cost of U.S.$78,286.04, resulting in an ICER of U.S.$30,330.15 per QALY, which was below the willingness-to-pay threshold of U.S.$38,142.56 per QALY. When the patient assistance program (PAP) was considered, the ICER became U.S.$1,730.67 per QALY, manifesting absolute cost-effectiveness. The results of sensitivity analyses demonstrated that pembrolizumab was cost-effective in most cases. Conclusions Pembrolizumab is a cost-effective first-line treatment for dMMR/MSI-H advanced or metastatic CRC patients in China, especially considering the PAP.

show abstract

Health Utilities Associated with Hemoglobin Levels and Blood Loss in Postmenopausal Women: The Women's Health Initiative

Abstract: Lower levels of Hgb and a loss of Hgb are associated with a statistically significant and clinically meaningful decrement in health utility in all postmenopausal women we studied and also in those with chronic conditions.

Cited by 7 publications

References 21 publications

Impact of non-cardiovascular comorbidities on the quality of life of patients with chronic heart failure: a scoping review

Impact of non-cardiovascular comorbidities on the quality of life of patients with chronic heart failure: a scoping review

The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation

Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer from the perspective of the Chinese health-care system

Contact Info

Product

Resources

About